The Indian indices closed Friday's trading session with sharp fall after initial gains. BSE Sensex and Nifty ended down by nearly 0.6 per cent and 0.56 per cent on the last day of the week, after registering handsome gains on a weekly basis.

Pharma major Lupin launched Levothyroxine tablets for which is had earlier received USFDA approval. The tablets are used to treat hypothyroidism and pituitary thyrotropin suppression.

Caplin Steriles, a 100 per cent subsidiary of Caplin Point Laboratories has received final approval by the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Glycopyrrolate injection USP.

Overall volumes in futures & options currently stand at 2.94 crore contracts with a turnover of Rs. 18,85,084 crore.

Overall volumes in futures & options currently stand at 2.94 crore contracts with a turnover of Rs. 18,85,084 crore.

Alembic Pharmaceuticals Limited received approval from the USFDA for azelastine hydrochloride ophthalmic solution, 0.05%, the company informed on Friday.

Shares of NTPC stood as the highest gainer amongst the S&P BSE Sensex post the company’s announcement of floating solar plants.

Following stocks are close to their 52-weeks low as at 1.03 p.m. on March 22, 2019.

The markets on March 22, 2019 opened up. BSE Sensex is trading at 38,363.11, up by 23.64 points and the Nifty is trading at 11,512.75, down by 15.60 points. 

Tata Power, a Tata Group company, bagged a contract from the Ministry of Defence for air surveillance equipment. The company will work in partnership with foreign OEM, Indra Sistemas, Spain.